Gleason score efficacy predictions in abiraterone acetate therapy with mCRPC

Share :
Published: 31 Jan 2014
Views: 4678
Dr Karim Fizazi - Institut Gustave Roussy, Paris, France

Dr Karim Fizazi of Institut Gustave Roussy in Paris, France at the ASCO GU congress 2014 explores the results of phase III trials looking at whether or not Gleason scores predict efficacy of abiraterone acetate therapy in patients with mCRPC.

The discussion includes the potential future of treatment options in CRPC, clinical strategies overcoming androgen resistance, treatment options available to patients with CRPC, correct sequencing for the use of newly available drug for CRPC management and identification of patient sub-groups that may optimally benefit from novel treatment approaches.


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).